India
· Delayed Price · Currency is INR Torrent Pharmaceuticals Statistics
Total Valuation
NSE:TORNTPHARM has a market cap or net worth of INR 1.16 trillion. The enterprise value is 1.19 trillion.
| Market Cap | 1.16T |
| Enterprise Value | 1.19T |
Important Dates
The next estimated earnings date is Monday, July 28, 2025.
| Earnings Date | Jul 28, 2025 |
| Ex-Dividend Date | Jun 20, 2025 |
Share Statistics
| Current Share Class | 338.45M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 103.96M |
Valuation Ratios
The trailing PE ratio is 60.91 and the forward PE ratio is 46.46.
| PE Ratio | 60.91 |
| Forward PE | 46.46 |
| PS Ratio | 10.11 |
| PB Ratio | 15.34 |
| P/TBV Ratio | 38.95 |
| P/FCF Ratio | 58.99 |
| P/OCF Ratio | 45.03 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.15, with an EV/FCF ratio of 60.29.
| EV / Earnings | 62.25 |
| EV / Sales | 10.33 |
| EV / EBITDA | 32.15 |
| EV / EBIT | 40.66 |
| EV / FCF | 60.29 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.43.
| Current Ratio | 1.19 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | 0.88 |
| Debt / FCF | 1.65 |
| Interest Coverage | 11.64 |
Financial Efficiency
Return on equity (ROE) is 26.46% and return on invested capital (ROIC) is 16.83%.
| Return on Equity (ROE) | 26.46% |
| Return on Assets (ROA) | 12.17% |
| Return on Invested Capital (ROIC) | 16.83% |
| Return on Capital Employed (ROCE) | 28.48% |
| Revenue Per Employee | 6.75M |
| Profits Per Employee | 1.12M |
| Employee Count | 17,059 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.15 |
Taxes
In the past 12 months, NSE:TORNTPHARM has paid 7.62 billion in taxes.
| Income Tax | 7.62B |
| Effective Tax Rate | 28.49% |
Stock Price Statistics
The stock price has increased by +14.83% in the last 52 weeks. The beta is 0.16, so NSE:TORNTPHARM's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +14.83% |
| 50-Day Moving Average | 3,247.21 |
| 200-Day Moving Average | 3,251.97 |
| Relative Strength Index (RSI) | 62.01 |
| Average Volume (20 Days) | 580,244 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:TORNTPHARM had revenue of INR 115.16 billion and earned 19.11 billion in profits. Earnings per share was 56.47.
| Revenue | 115.16B |
| Gross Profit | 87.40B |
| Operating Income | 29.26B |
| Pretax Income | 26.73B |
| Net Income | 19.11B |
| EBITDA | 36.76B |
| EBIT | 29.26B |
| Earnings Per Share (EPS) | 56.47 |
Balance Sheet
The company has 6.88 billion in cash and 32.50 billion in debt, giving a net cash position of -25.62 billion.
| Cash & Cash Equivalents | 6.88B |
| Total Debt | 32.50B |
| Net Cash | -25.62B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 75.91B |
| Book Value Per Share | 224.28 |
| Working Capital | 9.05B |
Cash Flow
In the last 12 months, operating cash flow was 25.85 billion and capital expenditures -6.12 billion, giving a free cash flow of 19.73 billion.
| Operating Cash Flow | 25.85B |
| Capital Expenditures | -6.12B |
| Free Cash Flow | 19.73B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.90%, with operating and profit margins of 25.41% and 16.60%.
| Gross Margin | 75.90% |
| Operating Margin | 25.41% |
| Pretax Margin | 23.21% |
| Profit Margin | 16.60% |
| EBITDA Margin | 31.92% |
| EBIT Margin | 25.41% |
| FCF Margin | 17.13% |
Dividends & Yields
This stock pays an annual dividend of 32.00, which amounts to a dividend yield of 0.97%.
| Dividend Per Share | 32.00 |
| Dividend Yield | 0.97% |
| Dividend Growth (YoY) | 14.29% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 56.67% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.97% |
| Earnings Yield | 1.64% |
| FCF Yield | 1.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 8, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Jul 8, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
NSE:TORNTPHARM has an Altman Z-Score of 10.74 and a Piotroski F-Score of 8.
| Altman Z-Score | 10.74 |
| Piotroski F-Score | 8 |